Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-1-3
pubmed:abstractText
In order to reduce side effects in the course of allergen specific immunotherapy hypoallergenic allergen derivatives with reduced IgE reactivity have been made by genetic engineering. In contrast to other recombinant hypoallergenic allergen derivatives which showed reduced IgE reactivity, a recombinant trimer of the major birch pollen allergen Bet v 1 showed reduced allergenic activity despite preserved IgE reactivity. We studied rBet v 1 trimer by SDS-PAGE, mass spectrometry, circular dichroism and gel filtration. Furthermore we investigated IgE and IgG reactivity of the rBet v 1 trimer in solid and liquid phase assays and compared its allergenic activity with that of rBet v 1 wildtype using basophil activation assays. In solid phase immunoassays rBet v 1 trimer exhibited even stronger IgE reactivity than the rBet v 1 wildtype, whereas both proteins were equally well recognized by Bet v 1-specific IgG antibody probes. In fluid phase IgE experiments rBet v 1 trimer inhibited IgE reactivity to rBet v 1 wildtype but showed a more than 10-fold reduced allergenic activity compared to the rBet v 1 monomer. By analytical gel filtration it was demonstrated that, despite its monomeric appearance in SDS-PAGE the trimer occurred in fluid phase in the form of defined high molecular weight (>600 kDa) aggregates whereas rBet v 1 wildtype strictly appeared as monomeric protein. The results indicate that the hypoallergenic nature of the rBet v 1 trimer is due to formation of defined high molecular weight aggregates which may be responsible for an altered presentation of IgE epitopes in a form with reduced capacity to crosslink effector-cell bound IgE. We thus provide evidence for a novel mechanism for hypoallergenic activity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1872-9142
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
431-41
pubmed:meshHeading
pubmed-meshheading:21093057-Animals, pubmed-meshheading:21093057-Antibodies, Monoclonal, pubmed-meshheading:21093057-Antibody Specificity, pubmed-meshheading:21093057-Antigen Presentation, pubmed-meshheading:21093057-Antigens, Plant, pubmed-meshheading:21093057-Basophils, pubmed-meshheading:21093057-Cell Line, pubmed-meshheading:21093057-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:21093057-Epitopes, pubmed-meshheading:21093057-Flow Cytometry, pubmed-meshheading:21093057-Humans, pubmed-meshheading:21093057-Hypersensitivity, pubmed-meshheading:21093057-Immunoglobulin E, pubmed-meshheading:21093057-Immunoglobulin G, pubmed-meshheading:21093057-Models, Immunological, pubmed-meshheading:21093057-Phosphoric Diester Hydrolases, pubmed-meshheading:21093057-Protein Structure, Quaternary, pubmed-meshheading:21093057-Pyrophosphatases, pubmed-meshheading:21093057-Rats, pubmed-meshheading:21093057-Recombinant Proteins, pubmed-meshheading:21093057-Solutions, pubmed-meshheading:21093057-Up-Regulation, pubmed-meshheading:21093057-beta-N-Acetylhexosaminidases
pubmed:year
2011
pubmed:articleTitle
Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer.
pubmed:affiliation
Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Vienna General Hospital (AKH), Medical University of Vienna, 1090 Vienna, Austria.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't